Q1 EPS Forecast for Lexaria Bioscience Lifted by Analyst

Lexaria Bioscience Corp. (NASDAQ:LEXX) – Equities researchers at HC Wainwright upped their Q1 2025 EPS estimates for Lexaria Bioscience in a research note issued to investors on Monday, November 25th. HC Wainwright analyst Y. Chen now forecasts that the company will earn ($0.08) per share for the quarter, up from their prior estimate of ($0.09). HC Wainwright currently has a “Buy” rating and a $10.00 target price on the stock. The consensus estimate for Lexaria Bioscience’s current full-year earnings is ($0.42) per share. HC Wainwright also issued estimates for Lexaria Bioscience’s Q2 2025 earnings at ($0.08) EPS, Q4 2025 earnings at ($8.00) EPS and FY2025 earnings at ($0.31) EPS.

Lexaria Bioscience Stock Down 0.9 %

NASDAQ LEXX opened at $2.13 on Wednesday. Lexaria Bioscience has a 1-year low of $1.20 and a 1-year high of $6.85. The firm’s fifty day simple moving average is $2.69 and its 200-day simple moving average is $3.01.

Hedge Funds Weigh In On Lexaria Bioscience

Several hedge funds have recently bought and sold shares of LEXX. Armistice Capital LLC acquired a new position in Lexaria Bioscience during the second quarter worth $2,836,000. Geode Capital Management LLC increased its position in Lexaria Bioscience by 31.0% during the third quarter. Geode Capital Management LLC now owns 150,391 shares of the company’s stock worth $459,000 after buying an additional 35,608 shares during the last quarter. Renaissance Technologies LLC acquired a new position in Lexaria Bioscience during the second quarter worth $63,000. HighTower Advisors LLC acquired a new position in Lexaria Bioscience during the third quarter worth $40,000. Finally, XTX Topco Ltd increased its position in Lexaria Bioscience by 47.8% during the third quarter. XTX Topco Ltd now owns 18,626 shares of the company’s stock worth $57,000 after buying an additional 6,024 shares during the last quarter. 13.06% of the stock is owned by institutional investors and hedge funds.

About Lexaria Bioscience

Lexaria Bioscience Corp. operates as a biotechnology company. It develops and out-licenses its patented drug delivery technology, DehydraTECH, which combines lipophilic molecules or active pharmaceutical ingredients with specific long-chain fatty acids and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing while promoting healthier oral ingestion methods.